One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Insomnia Treatment Market

[ 英語タイトル ] Insomnia Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0082903
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Merck & Co.
- Mylan N.V.
- Paratek Pharmaceuticals, Inc.
- Pfizer Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vanda Pharmaceuticals Inc.

[Report Description]

The global insomnia treatment market is expected to grow at a CAGR of 5.3% over the forecast period. Increasing prevalence of insomnia across the world, rising stress level, growing geriatric population, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market.

Development of new technologies and introduction of medical devices are anticipated to boost market growth. Only few medical devices have been approved in the recent years such as EBB Insomnia Therapy, Fisher Wallace Stimulator, and Alpha-Stim AID, which are expected to have higher penetration due to favorable reimbursement policies and adoption of device - drug combination therapies for treating insomnia.

The other factors such as side effects due to certain OTC and prescription medication, arthritis, high usage of media devices before sleep, are driving the number of people suffering from insomnia, thus boosting the market growth prospects. Moreover, the growth of psychological conditions and constantly increasing noise levels in the urban areas will also propel the insomnia treatment market, during the forecast period.

Key Market Trends

Orexin Antagonist segment is expected to grow in the forecast period

The global insomnia treatment market is segmented based on treatment type, which includes benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonist, melatonin antagonist, and other treatment types. The distribution channel includes hospital pharmacies, retail pharmacies and drug stores, and online pharmacies.

The insomnia drugs comprise of a wide range of patented drugs, as well as generics. The patented drugs hold a larger share in developed regions, owing to the better reimbursement policies. The orexin antagonist segment is expected to grow rapidly during the forecast period due to its greater efficacy than other drugs.

North America is expected to dominate the Insomnia Treatment market

North America leads the insomnia treatment market. The growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market over the forecast period. Along with this, the rise in awareness and high health care spending are also expected to drive the market. Other factors that will promote the demand for insomnia drugs includes rapidly growing geriatric population and rising prevalence of sleep disorders and stress.

Competitive Landscape

The insomnia treatment market is fragmented in nature owing to the presence of multiple generic manufacturers. A few players operating in the market offer branded drugs options, however, price sensitivity is an issue in several emerging regions. Additionally, major manufacturers are focusing on the development of new molecules to gain a competitive edge and tap the high unmet needs in the market. The major players in the market are Merck & Co., Mylan N.V., Paratek Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Stress Due to Highly Active Lifestyle of Individuals
4.2.2 Side Effects Due to Certain OTC and Prescription Medication
4.2.3 High Usage of Media Devices before Sleep
4.3 Market Restraints
4.3.1 Misconceptions about the Seriousness of Insomnia
4.3.2 Patient Non-Adherence due to Characteristic Side Effects of Insomnia Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment Type
5.1.1 By Drug Benzodiazepines Nonbenzodiazepines Antidepressants Orexin Antagonist Melatonin Antagonist Other Treatment
5.1.2 Devices
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies and Drug Stores
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Merck & Co.
6.1.2 Mylan N.V.
6.1.3 Paratek Pharmaceuticals, Inc.
6.1.4 Pfizer Inc.
6.1.5 Sanofi S.A.
6.1.6 Sumitomo Dainippon Pharma Co., Ltd.
6.1.7 Takeda Pharmaceutical Company Ltd.
6.1.8 Teva Pharmaceutical Industries Ltd.
6.1.9 Vanda Pharmaceuticals Inc.




Recommended reports